News

Dr Vinay Prasad's FDA exit in less than 3 months linked to Sarepta gene therapy controversy? Check details
Dr. Vinay Prasad, a controversial figure and critic of the FDA, resigned from his high-ranking position at the agency after ...
Controversial FDA official Dr. Vinay Prasad departs agency
Dr. Vinay Prasad, the controversial critic of the US Food and Drug Administration who took a top role at the regulatory ...
Who is Vinay Prasad? US FDA's top regulator exits agency after controversy over Sarepta gene therapy
Dr. Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene ...
Vinay Prasad, US FDA's chief medical and science officer, departs agency
Vinay Prasad, the Food and Drug Administration's chief medical and science officer, resigned. He cited a desire to return to ...
pharmaphorum2h
Vinay Prasad abruptly departs from the FDA
Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three ...
FDA vaccines head, chief medical officer Vinay Prasad departs agency
Vinay Prasad leaves FDA apparently due to backlash from the agency's handling of potential deaths related to Sarepta's ...
The New York Sun5h
FDA’s Top Regulator Is Out Amid MAHA Backlash Over Blocking Access to $3.2 Million Per Dose Therapy for Rare Disorder in Boys
Dr. Vinay Prasad, who came under fire from patient advocacy groups and Laura Loomer, is gone after less than three months on ...
Stocktwits on MSN6h
FDA Official Who Halted Sarepta’s Gene Therapy Resigns Amid Backlash Over Access To Duchenne Treatment
Vinay Prasad has stepped down as head of the FDA’s biologics division just two months into the job, following growing ...
FDA’s Prasad Exits After Sarepta Gene Therapy Controversy
Vinay Prasad, a top regulator at the US Food and Drug Administration, has left the agency after a controversy over his ...
Just The News7h
FDA allows distribution of muscular dystrophy drug again after public criticism
The agency’s now-reversed decision to halt distribution of a gene therapy for children suffering from muscular dystrophy ...
BioSpace8h
Prasad Out at CBER Following Sarepta Rollercoaster and Conservative Criticism
The FDA’s dramatic summer continues to unfold as news broke late Tuesday evening that Vinay Prasad will depart the agency, ...
PharmExec8h
Vinay Prasad Out as FDA CBER Head
Pharmaceutical Executive delivers strategic insights for pharma leaders, covering commercialization, market access, R&D, and ...